These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35746502)

  • 41. Immunogenicity and safety of the RTS,S/AS01 malaria vaccine co-administered with measles, rubella and yellow fever vaccines in Ghanaian children: A phase IIIb, multi-center, non-inferiority, randomized, open, controlled trial.
    Asante KP; Ansong D; Kaali S; Adjei S; Lievens M; Nana Badu L; Agyapong Darko P; Boakye Yiadom Buabeng P; Boahen O; Maria Rettig T; Agutu C; Benard Ekow Harrison S; Ntiamoah Y; Adomako Anim J; Adeniji E; Agordo Dornudo A; Gvozdenovic E; Dosoo D; Sambian D; Owusu-Boateng H; Ato Wilson E; Prempeh F; Vandoolaeghe P; Schuerman L; Owusu-Agyei S; Agbenyega T; Ofori-Anyinam O
    Vaccine; 2020 Apr; 38(18):3411-3421. PubMed ID: 32192811
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The compatibility of inactivated-Enterovirus 71 vaccination with Coxsackievirus A16 and Poliovirus immunizations in humans and animals.
    Mao Q; Wang Y; Shao J; Ying Z; Gao F; Yao X; Li C; Ye Q; Xu M; Li R; Zhu F; Liang Z
    Hum Vaccin Immunother; 2015; 11(11):2723-33. PubMed ID: 25715318
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comparative analysis of immunogenicity and safety of an enterovirus 71 vaccine between children aged 3-5 years and infants aged 6-35 months.
    Gu W; Zeng G; Hu YM; Hu YS; Zhang Y; Hu YL; Wang Y; Li JX; Zhu FC
    Expert Rev Vaccines; 2018 Mar; 17(3):257-262. PubMed ID: 29363365
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Short-term dynamic changes in neutralizing antibodies against enterovirus 71 after vaccination.
    Wang S; Zeng J; Zhang X; Gan Z; Fan J; Chen Y; Liang Z; Hu X; Zeng G; Lv H
    Hum Vaccin Immunother; 2020 Jul; 16(7):1595-1601. PubMed ID: 31977278
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunogenicity and safety of concurrent or sequential administration of live, attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) and measles-mumps-rubella vaccine in infants 9-12 months of age in the Philippines: A non-inferiority Phase 4 randomized clinical trial.
    Capeding MR; Alberto E; Feser J; Mooney J; Tang Y; Audet SA; Beeler JA; Ellison DW; Zhang L; Letson GW; Neuzil KM; Marfin AA
    Vaccine X; 2020 Dec; 6():100074. PubMed ID: 33005887
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and immunogenicity of inactivated hepatitis-A vaccine developed by Human Biologicals Institute in two age groups of healthy subjects: A phase I open label study.
    Susarla SK; Palkar S; Sv PS; Diwan A; Barsode S; Satish M; Rajashakar BC; Sandhya G; Lingala R; Sahoo DP
    Vaccine; 2021 Apr; 39(15):2088-2093. PubMed ID: 33741190
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A new measles mumps rubella (MMR) vaccine: a randomized comparative trial for assessing the reactogenicity and immunogenicity of three consecutive production lots and comparison with a widely used MMR vaccine in measles primed children.
    Lee CY; Tang RB; Huang FY; Tang H; Huang LM; Bock HL
    Int J Infect Dis; 2002 Sep; 6(3):202-9. PubMed ID: 12718836
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age.
    Nolan TM; Nissen MD; Naz A; Shepard J; Bedell L; Hohenboken M; Odrljin T; Dull PM
    Hum Vaccin Immunother; 2014; 10(2):280-9. PubMed ID: 24220326
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Co-administration of a meningococcal glycoconjugate ACWY vaccine with travel vaccines: a randomized, open-label, multi-center study.
    Alberer M; Burchard G; Jelinek T; Reisinger E; Beran J; Meyer S; Forleo-Neto E; Gniel D; Dagnew AF; Arora AK
    Travel Med Infect Dis; 2014; 12(5):485-93. PubMed ID: 24873986
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity and safety of a liquid Pentavalent (DTwP-Hb-Hib) combination vaccine manufactured by Human Biologicals Institute in 6-8 weeks old healthy infants: A phase III, randomized, single blind, non-inferiority study.
    Susarla SK; Gupta M; Mantan M; Dhongade R; Bhave S; Das RK; Ray RK; Ramesh Babu T; Ravi MD; Krishnamurthy B; James S; Sandhya G; Satish M; Sahoo DP
    Vaccine; 2019 Aug; 37(36):5452-5459. PubMed ID: 31331773
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunity and clinical efficacy of an inactivated enterovirus 71 vaccine in healthy Chinese children: a report of further observations.
    Liu L; Mo Z; Liang Z; Zhang Y; Li R; Ong KC; Wong KT; Yang E; Che Y; Wang J; Dong C; Feng M; Pu J; Wang L; Liao Y; Jiang L; Tan SH; David P; Huang T; Zhou Z; Wang X; Xia J; Guo L; Wang L; Xie Z; Cui W; Mao Q; Liang Y; Zhao H; Na R; Cui P; Shi H; Wang J; Li Q
    BMC Med; 2015 Sep; 13():226. PubMed ID: 26381232
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, Randomized, double-blind, placebo-controlled Trial.
    Li YP; Liang ZL; Xia JL; Wu JY; Wang L; Song LF; Mao QY; Wen SQ; Huang RG; Hu YS; Yao X; Miao X; Wu X; Li RC; Wang JZ; Yin WD
    J Infect Dis; 2014 Jan; 209(1):46-55. PubMed ID: 23922377
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An inactivated enterovirus 71 vaccine is safe and immunogenic in healthy adults: A phase I, double blind, randomized, placebo-controlled, study of two dosages.
    Tambyah PA; Oon J; Asli R; Kristanto W; Hwa SH; Vang F; Karwal L; Fuchs J; Santangelo JD; Gordon GS; Thomson C; Rao R; Dean H; Das SC; Stinchcomb DT
    Vaccine; 2019 Jul; 37(31):4344-4353. PubMed ID: 31230881
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Immunogenicity and Safety Profile for KM-248, a Combined Measles, Mumps, and Rubella Vaccine, and Its Noninferiority to the Measles Vaccine in Healthy Japanese Children: a Phase 3 Randomized Multicenter Single-Blind Clinical Trial.
    Platt H; Tochihara S; Oda Y; Ueda K
    Jpn J Infect Dis; 2021 Sep; 74(5):429-436. PubMed ID: 33518626
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials.
    Vesikari T; Esposito S; Prymula R; Ypma E; Kohl I; Toneatto D; Dull P; Kimura A;
    Lancet; 2013 Mar; 381(9869):825-35. PubMed ID: 23324563
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunogenicity and safety of a new liquid hexavalent combined vaccine compared with separate administration of reference licensed vaccines in infants.
    Mallet E; Fabre P; Pines E; Salomon H; Staub T; Schödel F; Mendelman P; Hessel L; Chryssomalis G; Vidor E; Hoffenbach A;
    Pediatr Infect Dis J; 2000 Dec; 19(12):1119-27. PubMed ID: 11144370
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study.
    Chen WH; Neuzil KM; Boyce CR; Pasetti MF; Reymann MK; Martellet L; Hosken N; LaForce FM; Dhere RM; Pisal SS; Chaudhari A; Kulkarni PS; Borrow R; Findlow H; Brown V; McDonough ML; Dally L; Alderson MR
    Lancet Infect Dis; 2018 Oct; 18(10):1088-1096. PubMed ID: 30120069
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized, open label trial to evaluate and compare the immunogenicity and safety of a novel liquid hexavalent DTwP-Hib/Hep B-IPV (EasySix™) to licensed combination vaccines in healthy infants.
    Mohanty L; Sharma S; Behera B; Panwar S; Paliwal C; Gupta A; Chilkoti DC; Singh A
    Vaccine; 2018 Apr; 36(17):2378-2384. PubMed ID: 29580640
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Immunogenicity and safety of a boost dose of measles, mumps, and rubella combined vaccine for 4-6 years old children].
    Xiao YH; Chang SY; Bai S; Zhao RM; Wang JH; Wang XQ; Yang YK; Ma YL; Liu XQ; Luo LY; Lyu M; Chen HP
    Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Jun; 42(6):1086-1091. PubMed ID: 34814512
    [No Abstract]   [Full Text] [Related]  

  • 60. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.
    Dbaibo G; El-Ayoubi N; Ghanem S; Hajar F; Bianco V; Miller JM; Mesaros N
    Drugs Aging; 2013 May; 30(5):309-19. PubMed ID: 23494214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.